奥沙利铂联合吉西他滨治疗晚期原发性肝癌疗效观察

杨燕; 王明喜; 汪子书; 王俊斌; 郑荣生; 杨燕; 王明喜; 汪子书; 王俊斌; 郑荣生

doi:10.13898/j.cnki.issn.1000-2200.2015.09.005

[1]

Mir O, Coriat R, Boudou-Rouquette P, et al.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib [J].Med Oncol,2012,29 (4):2793-2799.

[2]

Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/ leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31 (28):3501-3508.

[3]

中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946.

[4]

Lin CL,Kao JH.Optimal management of hepatocellular carcinoma: challenges and opportunities[J].J Gastroenterol Hepatol,2010,25 (8):1336-1338.

[5]

王斌,于志坚,霍旭东.奥沙利铂联合吉西他滨对肝癌细胞株 HEPG-2 生长抑制作用的研究[J].南通大学学报:医学版, 2010,30(4):260-262.